Research graph
References from Enzyme replacement therapy (ERT) combined with transient low-dose methotrexate (TLD-MTX) results in age- and disease-dependent immune profile changes in Infantile- vs. late-onset Pompe disease patients. Local targets link to admitted publications; unresolved targets remain external evidence.
Acid alpha-glucosidase deficiency (glycogenosis type II, Pompe disease)
10.2174/1566524024605789 · 2002 · External reference
Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease
10.1038/labinvest.3700484 · 2006 · External reference
Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients
10.1093/brain/awh384 · 2005 · External reference
A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease
10.1016/j.jpeds.2005.11.033 · 2006 · External reference
Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease
10.1203/pdr.0b013e3181b24e94 · 2009 · External reference
Genotype-phenotype correlation in Pompe disease, a step forward
10.1186/s13023-014-0102-z · 2014 · External reference
CRIM-negative infantile Pompe disease: characterization of immune responses in patients treated with ERT monotherapy
10.1038/gim.2015.6 · 2015 · External reference
Characterization of immune response in Cross-Reactive Immunological Material (CRIM)-positive infantile Pompe disease patients treated with enzyme replacement therapy
10.1016/j.ymgmr.2019.100475 · 2019 · External reference
Immunological challenges and approaches to immunomodulation in Pompe disease: a literature review
10.21037/atm.2019.05.27 · 2019 · External reference
An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease
10.1038/s41436-018-0270-7 · 2019 · External reference
Transient low-dose methotrexate generates B regulatory cells that mediate antigen-specific tolerance to alglucosidase alfa
10.4049/jimmunol.1303326 · 2014 · External reference
Immune tolerance induction to enzyme-replacement therapy by co-administration of short-term, low-dose methotrexate in a murine Pompe disease model
10.1111/j.1365-2249.2008.03602.x · 2008 · External reference
Expansion of immature, nucleated red blood cells by transient low-dose methotrexate immune tolerance induction in mice
10.1111/cei.13552 · 2020 · External reference
Immunophenotype associated with high sustained antibody titers against enzyme replacement therapy in infantile-onset Pompe disease
10.3389/fimmu.2023.1301912 · 2023 · External reference
Pompe disease diagnosis and management guideline
10.1097/01.gim.0000218152.87434.f3 · 2006 · External reference
Predicting cross-reactive immunological material (CRIM) status in Pompe disease using GAA mutations: lessons learned from 10 years of clinical laboratory testing experience
10.1016/j.ymgme.2011.11.025 · 2012 · External reference
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease
10.1016/j.jpeds.2006.02.035 · 2006 · External reference
Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker
10.1097/gim.0b013e3181a87867 · 2009 · External reference
The three human monocyte subsets: implications for health and disease
10.1007/s12026-012-8297-3 · 2012 · External reference
Assessing disease severity in Pompe disease: the roles of a urinary glucose tetrasaccharide biomarker and imaging techniques
10.1002/ajmg.c.31320 · 2012 · External reference
Baseline urinary glucose tetrasaccharide concentrations in patients with infantile- and late-onset Pompe disease identified by newborn screening
10.1007/8904_2014_366 · 2015 · External reference
Mapping the T helper cell response to acid α-glucosidase in Pompe mice
10.1016/j.ymgme.2012.03.009 · 2012 · External reference
Therapeutic options for the management of Pompe disease: current challenges and clinical evidence in therapeutics and clinical risk management
10.2147/tcrm.s334232 · 2022 · External reference
The mechanism of action of methotrexate
10.1016/s0889-857x(05)70358-6 · 1997 · External reference
Enzyme replacement therapy and immunotherapy lead to significant functional improvement in two children with Pompe disease: a case report
10.1186/s13256-024-04638-5 · 2024 · External reference
Methotrexate and its mechanisms of action in inflammatory arthritis
10.1038/s41584-020-0373-9 · 2020 · External reference
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis
10.1093/rheumatology/kem279 · 2008 · External reference
A context-aware interpretive framework for lymphocyte immunophenotyping by flow cytometry
10.3389/fimmu.2026.1788361 · 2026 · External reference
Decrease of B-cells and autoantibodies after low-dose methotrexate
10.1016/s0753-3322(03)00086-6 · 2003 · External reference
Distinct effects of methotrexate and etanercept on the B cell compartment in patients with juvenile idiopathic arthritis
10.1002/art.38736 · 2014 · External reference
Human monocyte subset distinctions and function: insights from gene expression analysis
10.3389/fimmu.2020.01070 · 2020 · External reference
Monocyte differentiation and heterogeneity: inter-subset and interindividual differences
10.3390/ijms24108757 · 2023 · External reference
Gene expression profiling reveals the defining features of the classical, intermediate, and nonclassical human monocyte subsets
10.1182/blood-2010-12-326355 · 2011 · External reference
The fate and lifespan of human monocyte subsets in steady state and systemic inflammation
10.1084/jem.20170355 · 2017 · External reference
Impact of different immunosuppressive regimens on antigen-presenting blood cells in kidney transplant patients
10.1159/000079807 · 2004 · External reference
Circulating CD14+ CD16+ monocytes are expanded in sarcoidosis patients
10.1111/j.1346-8138.2003.tb00424.x · 2003 · External reference
Pattern of human monocyte subpopulations in health and disease
10.1111/sji.12883 · 2020 · External reference
Liquid chromatographic assay for a glucose tetrasaccharide, a putative biomarker for the diagnosis of Pompe disease
10.1006/abio.2000.4838 · 2000 · External reference
Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease
10.1016/j.ymgme.2005.03.010 · 2005 · External reference
Methotrexate inhibits T cell proliferation but not inflammatory cytokine expression to modulate immunity in people living with HIV
10.3389/fimmu.2022.924718 · 2022 · External reference
The generation of antibody-secreting plasma cells
10.1038/nri3795 · 2015 · External reference
Regulation of plasma-cell development
10.1038/nri1572 · 2005 · External reference
Re-engaging cross-reactive memory B cells: the influenza puzzle
10.3389/fimmu.2012.00053 · 2012 · External reference
Memory B cells and plasma cells: the differentiative continuum of humoral immunity
10.1111/imr.13016 · 2021 · External reference
Understanding early-life adaptive immunity to guide interventions for pediatric health
10.3389/fimmu.2020.595297 · 2020 · External reference
Tissue-resident memory T cells: local specialists in immune defence
10.1038/nri.2015.3 · 2016 · External reference
Migration, maintenance and recall of memory T cells in peripheral tissues
10.1038/nri2496 · 2009 · External reference
T-cell immunoglobulin and ITIM domain (TIGIT) associates with CD8+ T-cell exhaustion and poor clinical outcome in AML patients
10.1158/1078-0432.ccr-15-2626 · 2016 · External reference
TIGIT promotes CD8+ T cells exhaustion and predicts poor prognosis of colorectal cancer
10.1007/s00262-021-02886-8 · 2021 · External reference
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
10.1038/ni.1674 · 2009 · External reference
Cutting edge: TIGIT has T cell-intrinsic inhibitory functions
10.4049/jimmunol.1003081 · 2011 · External reference
Blocking TIGIT/CD155 signalling reverses CD8(+) T cell exhaustion and enhances the antitumor activity in cervical cancer
10.1186/s12967-022-03480-x · 2022 · External reference
TIGIT signalling pathway negatively regulates CD4(+) T-cell responses in systemic lupus erythematosus
10.1111/imm.12715 · 2017 · External reference
Treg cells expressing the coinhibitory molecule TIGIT selectively inhibit proinflammatory Th1 and Th17 cell responses
10.1016/j.immuni.2014.02.012 · 2014 · External reference
Advances in immune tolerance induction in enzyme replacement therapy
10.1007/s40272-024-00627-9 · 2024 · External reference
Successful immune tolerance induction to enzyme replacement therapy in CRIM-negative infantile Pompe disease
10.1038/gim.2011.4 · 2012 · External reference
Benefits of prophylactic short-course immune tolerance induction in patients with infantile Pompe disease: Demonstration of long-term safety and efficacy in an expanded cohort
10.3389/fimmu.2020.01727 · 2020 · External reference
In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody
10.3233/hab-2004-13301 · 2004 · External reference
Rituximab induces a lasting, non-cumulative remodelling of the B-cell compartment
2019 · External reference
Role of regulatory cells in immune tolerance induction in hemophilia A
10.1097/hs9.0000000000000557 · 2021 · External reference
Peripherally generated Foxp3(+) regulatory T cells mediate the immunomodulatory effects of IVIg in allergic airways disease
10.4049/jimmunol.1502361 · 2017 · External reference
Update of the Pompe disease mutation database with 107 sequence variants and a format for severity rating
10.1002/humu.20745 · 2008 · External reference
